Natera, MyOme Launch Zenith Genomics with Long-Read Methylation Analysis in Q2 2026
Natera and MyOme launch Zenith portfolio offering premium exome and genome testing that integrates long-read methylation analysis to resolve variants of uncertain significance and imprinting conditions. Starting early Q2 2026, methylation analysis will be incorporated into all eligible rare disease exome and genome orders.
1. Partnership and Launch
Natera has teamed up with MyOme to introduce Zenith, a premium exome and genome testing portfolio that leverages MyOme’s genome-first platform. The collaboration combines Natera’s national clinical network and EMR integration with MyOme’s multi-omic innovations to enhance rare disease diagnostics.
2. Methylation Analysis Advantage
Zenith’s long-read sequencing approach simultaneously captures DNA sequence and methylation signatures, enabling resolution of variants of uncertain significance and imprinting conditions without separate epigenetic tests. This multi-omic capability addresses gaps in standard sequencing by detecting disease-related epigenetic patterns in a single workflow.
3. Commercial Rollout
The Zenith portfolio is now available for commercial order through Natera’s clinical network, with methylation analysis automatically integrated into all eligible rare disease exome and genome orders starting early Q2 2026. This rollout leverages Natera’s existing clinical support infrastructure and aims to shorten diagnostic timelines for rare disease patients.